Last reviewed · How we verify
Comparator - Trimbow®
Trimbow is a triple-combination inhaler that combines a long-acting beta-2 agonist, an inhaled corticosteroid, and a long-acting muscarinic antagonist to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease.
Trimbow is a triple-combination inhaler that combines a long-acting beta-2 agonist, an inhaled corticosteroid, and a long-acting muscarinic antagonist to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Comparator - Trimbow® |
|---|---|
| Also known as | Trimbow® - Beclomethasone Dipropionate 100 mcg/Formoterol Fumarate dihydrate 6 mcg/Glycopyrronium Bromide 12.5 mcg |
| Sponsor | Eurofarma Laboratorios S.A. |
| Drug class | Triple combination inhaler (ICS/LABA/LAMA) |
| Target | Beta-2 adrenergic receptor, glucocorticoid receptor, muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Trimbow delivers beclomethasone (ICS), formoterol (LABA), and glycopyrronium (LAMA) in a single inhaler. The corticosteroid reduces airway inflammation, the beta-2 agonist provides rapid and sustained bronchodilation, and the muscarinic antagonist provides additional bronchodilation through a different mechanism. This triple therapy addresses multiple pathophysiological pathways in COPD simultaneously.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Cough
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |